Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02574767
Other study ID # Fondecyt #1150878
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2015
Est. completion date February 2019

Study information

Verified date October 2015
Source University of Chile
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In Chile, 1 out of 4 pregnant women is obese (BMI > 30 kg/m2). This impacts negatively the health of the mother and the offspring during pregnancy. Lifestyle interventions are the primary prevention strategy for gestational diabetes in obese women; however, these interventions have shown null or limited effectiveness. In animals, n-3 long-chain polyunsaturated fatty acid (n3LC-PUFAs) have shown to increase insulin sensitivity through higher production and secretion of adipokines, enhanced fatty acids oxidation, reduction of lipogenesis, and direct anti-inflammatory effects; however evidence in humans and during pregnancy is still very limited. Combining a lifestyle intervention with n3LC-PUFAs supplementation could enhance the metabolic control of obese pregnant women. Objective: to assess the effectiveness of two prenatal nutritional interventions (home-based diet and physical activity counseling and/or n3LC-PUFAs supplementation) delivered to obese pregnant women in achieving better metabolic control in both the mother (lower incidence of gestational diabetes mellitus) and the offspring (lower incidence of macrosomia and lower prevalence of insulin resistance at birth).

Methods: this study is a cluster-randomized trial in which obese pregnant women from 12 primary health care centers (PHCC) will be stratified by socio-economic status (SES) and randomized to one of four parallel study arms. We will recruit 1000 women allocated to: 1 Home-based Diet and physical activity (PA) plus n3LC-PUFAs supplementation (Intervention Group 1, n=250); 2. Routine diet & PA counseling care plus n3LC-PUFAs supplementation (Intervention Group 2, n=250); 3. Home-based Diet and Physical activity plus placebo for n3LC-PUFA supplementation (Intervention Group 3, n=250); 4. Routine diet & PA counseling plus placebo (Control Group, n=250). Expected results: we expect that the intervention will contribute to achieving a better metabolic control during pregnancy. Ultimately, we expect that this study will contribute to advance the understanding of how to develop and implement effective actions to promote healthier pregnancies and therefore, healthier lives for mothers and their offsprings.


Description:

Obesity and related non-communicable chronic diseases (NCDs: cardiovascular diseases, cancer and diabetes) represent the main causes of death and disability in Chile as well as worldwide. They account for an important proportion of health-care costs and loss of productivity, overloading a country's economy, particularly in developing countries. From a population perspective, it is now clear that preventing the emergence of these conditions is the most effective approach; however most of the current policies fail to incorporate scientific knowledge and thus, are not effective or sustainable. There is now compelling evidence that although obesity and NCDs are mainly observed in adulthood, the risk for most of these conditions originates in the first 1000-days of life (i.e. from pregnancy to two years old). Maternal lifestyle and conditions during pregnancy (e.g. maternal obesity) could affect not only future maternal health, but also risk for NCDs in the next generation. Therefore, pregnancy is a critical window in the implementation of NCDs prevention strategies. Most of the interventions on diet and physical activity (PA) during pregnancy have focused on decreasing gestational weight gain (GWG). Recent meta-analyses of interventions have demonstrated that lifestyle interventions during pregnancy can have a positive effect on GWG. Beyond lifestyle interventions, other dietary interventions have been proposed such as probiotics, vitamin D or n-3 long chain polyunsaturated fatty acids (n3LC-PUFAs) supplementation. Regarding n3LC-PUFAs, differences in plasma fatty acid profiles between women with gestational diabetes (GDM) and women without GDM suggest a possible alteration in fatty acid metabolism in GDM. Data from systematic reviews show a consistent association between marine or algae oil supplementation with higher length of gestation, improvement in maternal mood and neural development. Nonetheless, few interventions on diet and PA have focused on metabolic control in obese women and their impacts have not been consistent. Additionally, few intervention studies have explored the effect of n3LC-PUFAs supplementation on pregnant women in the incidence of GDM, with no studies conducted in obese pregnant women. Therefore, combining an n3LC-PUFAs supplementation with a lifestyle intervention could enhance the metabolic control of obese pregnant women. We propose to evaluate the effects of an n3LC-PUFAs supplementation intervention among obese pregnant women (independently and combined with a diet and physical activity intervention) on metabolic control in mothers and their offspring.

In 2013 we started in 12 primary health clinics (PHCC) of the South East area of Santiago Chile a cluster randomized trial -the Chilean Maternal & Infant Nutrition Cohort Study (CHiMINCs)- that aims to improve weight control during pregnancy and offspring growth during infancy by enhancing PHCC's maternal and infant weight monitoring systems as well as promoting breastfeeding. In the current study we propose to expand that effort trying to optimize metabolic control of obese pregnant women and their offspring by combining home-based diet and physical activity counseling and n3LC-PUFAs supplementation. Women who seek prenatal care in any of the 12 selected PHCC with <14 weeks gestation at first prenatal visit; body mass index (BMI) >30 Kg/m2 at first prenatal visit; have a singleton pregnancy will be asked to participate. We will recruit 1000 women; 250 women per arm of the study. After randomization, obese pregnant women in the intervention group 1 will receive home-based Diet & Physical activity (PA) counseling plus n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day). Obese pregnant women in the intervention group 2 will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions, plus n3LC-PUFAs supplementation of 800 mg of DHA. Obese pregnant women in the intervention group 3 will receive the home-based diet & PA counseling sessions plus n3LC-PUFAs placebo that will consist of S-oil containing 200 mg DHA/day. Placebo will be administered as capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation. The control group will receive routine diet & PA PHCC counseling sessions plus placebo (4 capsules of 50 mg DHA per day). Measurements will be collected at baseline (<14 weeks of pregnancy), mid-pregnancy (24-28 weeks), and at delivery. Baseline and 24-28 weeks measurements will be carried out at home.

Analyses will be done according both to the "intention-to-treat" (i.e. effectiveness approach) and "per protocol" (i.e. efficacy approach) principles. In accordance with the 2×2 factorial design, the diet & PA intervention (Intervention Groups 1 and 3) will be compared to the routine care intervention (Intervention Groups 2 and Control Group) and the n3LC-PUFAs supplementation intervention (Intervention Groups 1 and 2) will be compared to placebo (Intervention Group 3 and Control Group). To evaluate the effects of the two combined interventions the outcomes in each of the 3 intervened groups will be compared between them and with the outcomes in the control group. We expect that the intervention will contribute to achieving a better metabolic control during pregnancy. Ultimately, we expect that this study will contribute to advance the understanding of how to develop and implement effective actions to promote healthier pregnancies and therefore, healthier lives for mothers and their offsprings.


Recruitment information / eligibility

Status Completed
Enrollment 1002
Est. completion date February 2019
Est. primary completion date February 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- =14 weeks gestational age at first prenatal visit

- Body mass index (BMI) >30 Kg/m2 at first prenatal visit

- Have a singleton pregnancy

- Plan to deliver at the "Sotero del Rio Hospital".

Exclusion Criteria:

- Preexisting diabetes (known or diagnosed at first control (Fasting Plasma Glucose > 126 mg/dl or 2h plasma glucose > 200 mg/dl during an oral glucose tolerance test (OTTG))

- Insulin or metformin use

- Known medical or obstetric complications which restrict physical activity

- History of eating disorders

- High risk for hemorrhagic bleeding

- High risk pregnancy according to national guidelines

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Lifestyle counseling
Obese pregnant women from PHCC randomized to this group will receive Home-based Diet & Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
Dietary Supplement:
PUFA Supplementation
Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
Behavioral:
Routine diet & PA
Obese pregnant women from PHCC randomized to this group will receive will receive routine diet & PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
Dietary Supplement:
PUFA placebo
Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.

Locations

Country Name City State
Chile Institute of Nutrition and Food Technology Santiago

Sponsors (4)

Lead Sponsor Collaborator
University of Chile Corporación de Apoyo de la Investigación Científica en Nutrición, DSM Nutritional Products, Inc., Fondo Nacional de Desarrollo Científico y Tecnológico, Chile

Country where clinical trial is conducted

Chile, 

Outcome

Type Measure Description Time frame Safety issue
Primary Gestational Diabetes Mellitus (GDM) According to ADA 2011 guidelines (fasting glucose =92 mg/dL and/or 2 h after =153 mg/dL) 24-28 weeks of gestation
Primary Macrosomia Birth weight greater than 4000 g At birth
Primary Prevalence of insulin resistance Prevalence of insulin resistance (IR) defined as cord blood homeostasis model assessment-estimated insulin resistance (HOMA-IR) > 2.60 at birth. At birth
Secondary Low Birth Weight Birth weight below 2500 g At birth
Secondary Excess weight gain during pregnancy Weight at delivery minus the pregestational weight Self reported pre-gestational weight, weight gain will be measured at least three times at 10-14, 24-28, 35-37 weeks of gestation, and also at delivery
Secondary Pre-eclampsia Blood pressure = 140 mm Hg systolic or = 90 mm Hg diastolic 24-28 weeks of gestation
Secondary Preterm delivery Child´s birth < 37 weeks gestational age At birth
Secondary Proportions of cesareans Proportion of children delivered via cesarean section divided total of deliveries At birth
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2